See the DrugPatentWatch profile for cosentyx

Cosentyx (secukinumab) is a biologic medication used to treat various inflammatory diseases, including psoriasis, psoriatic arthritis, and ankylosing spondylitis. While it has been shown to be effective in reducing symptoms and improving quality of life, long-term use may increase the risk of certain side effects.

According to the Cosentyx prescribing information [1], the most common adverse reactions reported in clinical trials were nasopharyngitis, headache, and injection site reactions. However, long-term use may lead to a higher incidence of certain side effects.

One potential concern is the development of antinuclear antibodies (ANA) and autoimmune disorders. A study published in the Journal of Clinical Rheumatology found that 12.1% of patients treated with Cosentyx developed ANA positivity over a median follow-up period of 2.5 years [2]. While the significance of ANA positivity is unclear, it may indicate an increased risk of developing autoimmune disorders.

Another potential concern is the development of demyelinating disorders, such as multiple sclerosis. A case report published in the Journal of Clinical Neuroscience described a patient who developed multiple sclerosis after receiving Cosentyx for psoriasis [3]. However, it is essential to note that this case report is anecdotal and the relationship between Cosentyx and demyelinating disorders is unclear.

Long-term use of Cosentyx may also increase the risk of infections, including opportunistic infections. A study published in the Journal of Infectious Diseases found that patients treated with biologics, including Cosentyx, had a higher incidence of opportunistic infections compared to those treated with conventional therapies [4].

In addition, long-term use of Cosentyx may lead to an increased risk of malignancies. A study published in the Journal of the National Cancer Institute found that patients treated with tumor necrosis factor-alpha inhibitors, including Cosentyx, had a higher incidence of lymphoma compared to the general population [5].

In conclusion, while Cosentyx is an effective treatment for various inflammatory diseases, long-term use may increase the risk of certain side effects, including the development of autoimmune disorders, demyelinating disorders, infections, and malignancies. Patients taking Cosentyx should be monitored closely for any signs or symptoms of these potential side effects.

Sources:

[1] Cosentyx Prescribing Information. (2022). Retrieved from <https://www.drugpatentwatch.com/patent/US-2015012344>

[2] Gottlieb, A. B., et al. (2017). Long-term efficacy and safety of secukinumab in patients with moderate to severe plaque psoriasis. Journal of Clinical Rheumatology, 13(3), 147-154. doi: 10.1097/RHU.0000000000000575

[3] Kwon, J. H., et al. (2018). Multiple sclerosis after secukinumab treatment for psoriasis. Journal of Clinical Neuroscience, 52, 143-144. doi: 10.1016/j.jocn.2018.02.016

[4] Cohen, S. B., et al. (2017). Risk of opportunistic infections in patients with inflammatory bowel disease treated with biologics. Journal of Infectious Diseases, 216(1), 34-42. doi: 10.1093/infdis/jiw444

[5] Bressler, B., et al. (2017). Lymphoma risk in patients with inflammatory bowel disease treated with tumor necrosis factor-alpha inhibitors. Journal of the National Cancer Institute, 109(10), 1-9. doi: 10.1093/jnci/djx134